S-1 developed as a novel oral fluoropyrimidine delivative in Japan is a potent antitumor drug in cancer including colorectal and gastric cancer. Several studies have recently demonstrated the efficacy of S-1 in both the single administration and combination settings for the treatment of unresectable advanced colorectal cancer. Also, clinical trials are progressing for adjuvant therapy after curative resection of colon and rectal cancer. In this minireview, we comment on the therapeutic efficacy of S-1 for colorectal cancer.
Buy this Article